SCHEMBL25326508

SCHEMBL25326508

Fc1ccc(-c2cnccn2)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.49
NPY5R Q15761 1/20 0.49
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
PKM P14618 1/20 0.44
NISCH Q9Y2I1 1/20 0.44
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CB P42338 1/20 0.43
PI4KA P42356 1/20 0.43
PIK3CG P48736 1/20 0.43
PI4KB Q9UBF8 1/20 0.43
KDR P35968 1/20 0.43
HSD11B1 P28845 2/20 0.42
NR1I2 O75469 1/20 0.42
CASP1 P29466 1/20 0.42
P2RX7 Q99572 1/20 0.42
ALOX5AP P20292 2/20 0.42
FEN1 P39748 2/20 0.42
CYP2D6 P10635 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6960490 0.84 NPY5R (0.65) KMONPY5RNPC1RAB9APKM
SCHEMBL16640379 0.84 ALOX5AP (0.48) KMONPY5RNPC1RAB9APIK3CD
SCHEMBL2409087 0.79 PIM1 (0.46) NPC1RAB9APIK3CDPIK3CAPIK3CB
SCHEMBL12492145 0.79 CYP3A4 (0.52) KMONPY5RNPC1RAB9APKM
SCHEMBL30112660 0.78 GRIN2B (0.48) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL10353034 0.77 RAB9A (0.60) NPY5RNPC1RAB9APKMPIK3CD
SCHEMBL27642885 0.77 RAB9A (0.50) KMONPY5RNPC1RAB9APKM
SCHEMBL29901515 0.77 RAB9A (0.50) KMONPY5RNPC1RAB9APKM
SCHEMBL2559473 0.76 KMO (0.49) KMONISCHPIK3CDPIK3CAPIK3CB
SCHEMBL21044391 0.76 ALOX5AP (0.51) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282749-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-09-11 US disclosed
EP-4469445-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
CN-116924995-A Method for synthesizing benzimidazole compound by catalyzing L-phenylalanine 宁夏师范学院 2023-10-24 CN disclosed
WO-2023146991-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146991-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282749-A1 COMPOUNDS AND METHODS OF USE CYP1B1, CYP2C19, UGT1A1 KMO 2021/4885NPY5R 480/4885NPC1 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.